A single dose, randomised, double blind, double dummy, placebo controlled, 3-way crossover clinical study, comparing the onset of relief from methacholine-induced bronchoconstriction with CHF1535 100/6 μg NEXThaler versus CHF1535 100/6 μg pMDI in asthmatic patients.

Trial Profile

A single dose, randomised, double blind, double dummy, placebo controlled, 3-way crossover clinical study, comparing the onset of relief from methacholine-induced bronchoconstriction with CHF1535 100/6 μg NEXThaler versus CHF1535 100/6 μg pMDI in asthmatic patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Beclometasone/formoterol (Primary) ; Beclometasone/formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Chiesi Farmaceutici SpA
  • Most Recent Events

    • 06 Nov 2017 Status changed from recruiting to completed.
    • 06 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top